Greg Caldwell Email & Phone Number

Spokane, Wa, Us

San Francisco, California, Us

Boston, Ma, Us

Led day-to-day management and execution of engagements, with oversight of 2-4 person teams (Associates, MDs, PhDs). Delivered insights and recommendations to drive growth and value creation for clients.Outlined clients’ strategic issues, designed and oversaw all analyses, developed the narrative and structure of presentations, and communicated engagement conclusions.Select Engagements:- Led big pharma’s gene therapy portfolio review and strategy refresh / development to improve its market leadership; identified ~30 assets from >500 program screen to amplify its portfolio. Client in-licensed multiple assets.- Defined commercial potential of an emerging biotech’s kinase inhibitor for rare genetic and acquired cardiac diseases. In parallel, developed an indication ordering and pricing strategy to maximize revenue and minimize R&D costs of the asset. Client integrated insights to optimize clinical development plan.- Conducted search and evaluation assessment of ~2K NICU and PICU clinical and commercial assets, identifying ~10 in-licensing options to drive top-line growth and commercial synergy for a life sciences company.- Conducted vendor due diligence of a ~$4B physician practice group for 2 global tier-1 PE funds; assessed the vitreoretinal landscape across 7 market scenarios to characterize the impact of emerging therapies on competitor market share, implications for practice profitability, and positioning for near-term M&A. Target was acquired in $4B+ acquisition deal.- Led clinical and commercial assessment of a big pharma’s projected blockbuster asset targeting cardiac and kidney conditions to determine optimal clinical trial design for late-stage clinical studies.- Led top-down and bottom-up launch readiness assessment of biotech's novel microbiome therapeutic, identifying potential risks and proposing solutions pertaining to its market access strategy, commercial potential, profitability metrics, and select launch tactics.

Boston, Ma, Us

South San Francisco, California, Us

Advised product and organizational development for emerging / mid-cap biotechs in the US & EU. Owned multiple workstreams and analyses across several engagements simultaneously, while managing select client relationships. Member of the Rare Disease Center of Excellence.Select Engagements:- Defined US & EU early commercialization strategy for biopharma's LVV and AVV gene therapies targeting rare immunodeficiency disorders and hematologic diseases. Identified recommended go-to-market models, based on forecasted revenue, expected organizational design and operating expenses, risk-adjusted net present value (rNPV), and strategic fit with portfolio.- Designed, developed, and facilitated 10 workshops and 2 competitive simulations with ~20 global, cross-functional leaders to define a big pharma’s global respiratory syncytial virus program and competitive response strategy.- Developed cross-functional launch strategy, tactical plan, and supporting organizational blueprint for a biotech’s disease-modifying monoclonal antibody targeting CD3; product launched and company acquired in multi-billion dollar deal.- Developed buy / build / partner models and launch plans for novel diagnostic tool of a venture-backed FemTech firm.

South San Francisco, California, Us

Ny, New York, Us

As a venture partner and investor, engaged in deal sourcing and preliminary evaluations of Seed and Series A healthcare and life sciences start-ups. Attended healthcare, scientific, and investor conferences to identify investment opportunities. Select opportunities assessed included novel therapeutics, innovative clinical care models, and next-generation medical devices.As an independent strategic advisor, provided corporate finance advisory services to support early stage biotech organizations focused on precision and regenerative medicine. Supporting activities included:- ADVISORY: Built investment theses and business cases outlining dynamics of the competitive market landscape, technical due diligence, product & corporate strategy, intellectual property, operational planning, financials & valuation, and exit strategy for clients. Select engagement examples below: - Conducted comprehensive due diligence and organizational gap assessment of a Series B pre-clinical diabetes-focused biotech, identifying areas to improve investor materials and product positioning to increase likelihood to achieve its fundraising objectives. - Developed a comprehensive sell-side due diligence report and other supporting investor materials (e.g., organizational development plan, virtual data room) for a pre-clinical cardiac regenerative medicine biotech; materials supported organization in achieving its Series A fundraising objectives.- BUSINESS DEVELOPMENT: Assessed industry dynamics to support relationship management with VC funds and startups. Created database to support screening and development of qualified targets; developed proposals that led to project wins within the regenerative medicine space. Developed materials and templates to support development of proposals, due diligence packages, pitch presentations, and investment memorandum.

Chicago, Il, Us

Executed CDDs and market assessments, generating critical insights and recommendations for life sciences clients. Developed disease and product profiles, defined existing and emerging standards of care, and mapped competitive landscapes. Designed and developed databases supporting competitive benchmarking, provider mapping, and payer segmentation analyses.Select Engagements:- Conducted search and evaluation assessment of 250+ molecules, identifying ~15 attractive candidates for emerging biotech’s drug delivery device based on scientific and commercial criteria: viability for use with device, commercial opportunity, dose dependency, and bioavailability.- Conducted equity research to characterize payer perspectives towards hemophilia and factor VIII drugs.- Assessed intra-abdominal and UTI markets to highlight commercial considerations for pharma’s penem antibiotic.

Chicago, Il, Us

Supported translational studies focused on investigating acute and evolving neuropathology of traumatic brain injury in neurogenerative diseases such as Alzheimer's disease and epilepsy.Leveraged controlled cortical impact animal models, advanced neuroimaging, and serum biomarker techniques to further assess mechanisms of white matter degeneration in neural networks of post-traumatic brain injured mice and deceased epileptic patients.

Bachelor Of Arts (B.A.), Ecology And Evolutionary Biology

Master Of Business Administration - Mba

Certificate, Systems Thinking

Certificate, Stem Cell Therapeutics (In Progress)